Eiger BioPharmaceuticals, Inc. (EIGR) News
Filter EIGR News Items
EIGR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EIGR News Highlights
- EIGR's 30 day story count now stands at 3.
- Over the past 15 days, the trend for EIGR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
Latest EIGR News From Around the Web
Below are the latest news stories about EIGER BIOPHARMACEUTICALS INC that investors may wish to consider to help them evaluate EIGR as an investment opportunity.
Some Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Just Made A Major Cut To Next Year's EstimatesToday is shaping up negative for Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders, with the analysts... |
Loss-Making Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Expected To Breakeven In The Medium-TermWith the business potentially at an important milestone, we thought we'd take a closer look at Eiger... |
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdateEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update. |
Eiger BioPharma's Single Dose Of Peginterferon Lambda Cuts Risk Of COVID-19-Related Hospitalizations, DeathsEiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. The data exhibited that among predominantly vaccinated participants with COVID-19, a single-dose treatment with Eiger's investigational agent, peginterferon lambda, resulted in significantly decreased clinical events. The primary endpoint was a composite endpoint of COVID-19-related hospitalization o |
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine (NEJM). The study, which evaluated newly diagnosed outpatients with mild-to-moderate COVID-19, found that among predominantly vaccinated p |
7 Cheap But Risky Biotech StocksBiotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%. |
The Scientific Founder & Independent Director of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), Jeffrey Glenn, Just Bought 43% More SharesPotential Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) shareholders may wish to note that the Scientific Founder... |
Newsflash: Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Analysts Have Been Trimming Their Revenue ForecastsOne thing we could say about the analysts on Eiger BioPharmaceuticals, Inc. ( NASDAQ:EIGR ) - they aren't optimistic... |
Eiger BioPharmaceuticals Announces Leadership ChangePALO ALTO, Calif., December 15, 2022--Eiger BioPharmaceuticals, Inc. ("Eiger" or "the company") (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, and its Board of Directors today announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately. |
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary EndpointEiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced topline primary Week 48 data from its landmark Phase 3 D-LIVR study (N=407) evaluating lonafarnib, a first-in-class prenylation inhibitor, in two regimens in patients with chronic HDV: lonafarnib boosted with ritonavir alone (all-oral) and in combination with peginterferon alfa (c |